Last reviewed · How we verify
rasagiline (Pharmacodynamics)
Rasagiline is a selective monoamine oxidase type B (MAO-B) inhibitor that increases dopamine levels in the brain by preventing its breakdown.
Rasagiline is a selective monoamine oxidase type B (MAO-B) inhibitor that increases dopamine levels in the brain by preventing its breakdown. Used for Parkinson's disease (early stage, as monotherapy), Parkinson's disease (advanced stage, as adjunctive therapy with levodopa).
At a glance
| Generic name | rasagiline (Pharmacodynamics) |
|---|---|
| Sponsor | University of Maryland, Baltimore |
| Drug class | Monoamine oxidase B (MAO-B) inhibitor |
| Target | MAO-B (Monoamine oxidase type B) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
By selectively inhibiting MAO-B, rasagiline reduces the enzymatic degradation of dopamine in the striatum and other brain regions affected by Parkinson's disease. This leads to increased dopamine availability, which helps restore motor function and reduce parkinsonian symptoms. The drug may also have neuroprotective properties independent of its MAO-B inhibition.
Approved indications
- Parkinson's disease (early stage, as monotherapy)
- Parkinson's disease (advanced stage, as adjunctive therapy with levodopa)
Common side effects
- Headache
- Dizziness
- Nausea
- Dyspepsia
- Orthostatic hypotension
- Insomnia
Key clinical trials
- A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension (PHASE1)
- Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rasagiline (Pharmacodynamics) CI brief — competitive landscape report
- rasagiline (Pharmacodynamics) updates RSS · CI watch RSS
- University of Maryland, Baltimore portfolio CI